2020

06/05/2020

The company has undertaken extensive safety measures for its employees straight after the outbreak, while ensuring continuity of operations and production

Abano Terme (PD), May 5th 2020 – Fidia, Italian multinational company, with R&D, manufacturing,…
27/04/2020

Health and safety, a top priority for Fidia

According to Fidia Farmaceutici S.p.A mission and policy, health and safety of people, and of course…
11/03/2020
Fidia has implemented a series of measures, to minimize any potential risks related with the…
10/03/2020
Fidia proudly supports the important aim of the World Sleep Day and launches the SLEEP&HEART…
13/01/2020

The Italian Group has announced a new commercial agreement with the multinational company Novartis for high-level products

Fidia has recently announced a new commercial partnership with the Italian subsidiary of Novartis…
02/12/2019
Fidia's wholly owned subsidiary, Fidia Pharma USA Inc., introduces in the US, TRILURON™ , a…
02/09/2019

The Italian company has announced two major investments in Spain with the acquisition of three ophthalmic products on the Spanish market from the multinational company Novartis, and the acquisition of the Spanish company Soluciones Bioregenerativas SL.

Fidia, an Italian multinational pharmaceutical company, has announced the acquisition of three…

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine